Details

Autor(en) / Beteiligte

• Yoneyama, Tohru
• Ohyama, Chikara
• Hatakeyama, Shingo
• Narita, Shintaro
• Habuchi, Tomonori
• Koie, Takuya
• Mori, Kazuyuki
• Hidari, Kazuya I.P.J.
• Yamaguchi, Maho
• Suzuki, Takashi
• Tobisawa, Yuki

Titel

Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer

Ist Teil von

• Biochemical and biophysical research communications, 2014-06, Vol.448 (4), p.390-396

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• •We developed novel immunoassay to measure aberrant glycosylated PSA (S2,3PSA).•Serum S2,3PSA in PCa group was significantly higher than that in non-PCa group.•The area under the curve of S2,3PSA assay was significantly higher than conventional PSA.•We examined that LNCaP cells produce PCa-associated S2,3PSA.•S2,3PSA may improve the accuracy of PCa detection and reduce unnecessary biopsy. We previously identified prostate cancer (PCa)-associated aberrant glycosylation of PSA, where α2,3-linked sialylation is an additional terminal N-glycan on free PSA (S2,3PSA). We then developed a new assay system measuring S2,3PSA using a magnetic microbead-based immunoassay. We compared the diagnostic accuracy of conventional PSA and percent-free PSA (%fPSA) tests. We used MagPlex beads to measure serum S2,3PSA levels using anti-human fPSA monoclonal antibody (8A6) for capture and anti-α2,3-linked sialic acid monoclonal antibody (HYB4) for detection. We determined the cutoff values in a training test and measured serum S2,3PSA levels in 314 patients who underwent biopsy, including 138 PCa and 176 non-PCa patients with PSA of <10.0ng/ml. Serum S2,3PSA levels were presented as mean fluorescence intensity (MFI). Receiver operating characteristic curves were used to evaluate the diagnostic accuracy of total PSA, %fPSA, and S2,3PSA. We determined an MFI cutoff value of 1130 with a sensitivity of 95.0% and specificity of 72.0% for the diagnosis of PCa in the training test. In the validation study, the area under the curve for the detection of PCa with S2,3PSA was 0.84, which was significantly higher than that with PSA or %fPSA. Although the present study is small and preliminary, these results suggest that the measurement of serum S2,3PSA using a magnetic microbead-based immunoassay may improve the accuracy of early detection of PCa and reduce unnecessary prostate biopsy.